• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Weight-based rt-PA thrombolysis protocol for acute native arterial and bypass graft occlusions.

作者信息

Arepally Aravind, Hofmann Lawrence V, Kim Hyun S, Geschwind J F, Kirkwood Sharon, Oechsle Denise, Perler Bruce

机构信息

Russell H. Morgan Department of Radiology and Radiological Science, Division of Cardiovascular and Interventional Radiology, Johns Hopkins Medical Institutes, Baltimore, Maryland, USA.

出版信息

J Vasc Interv Radiol. 2002 Jan;13(1):45-50. doi: 10.1016/s1051-0443(07)60008-6.

DOI:10.1016/s1051-0443(07)60008-6
PMID:11788694
Abstract

PURPOSE

To determine technical success and complications with weight-adjusted dosing of recombinant tissue plasminogen activator (rt-PA) for arterial and bypass graft occlusions.

MATERIALS AND METHODS

During an 8-month period, prospective data were collected on patients undergoing catheter-directed thrombolysis. Retrospective review of all medical charts and blood bank data were performed for confirmation. All patients underwent a standard weight-adjusted protocol for catheter-directed thrombolysis. Thrombolytic therapy with rt-PA (0.2 mg/mL) was defined as low-dose when 0.02 mg/kg/h rt-PA was used and high-dose when 0.04 mg/kg/h of rt-PA was used. Low-dose heparin therapy was used. Total infusion time, total dose, and hourly rate of dose were calculated. Technical success, defined as complete removal of all clot without surgical intervention, complications, and frequency of transfusions were tabulated.

RESULTS

A total of 35 patients underwent catheter-directed thrombolysis with rt-PA, including a total of 21 bypass grafts (60%) and 14 native arteries (40%). Mean age was 57 years (+/- 22.5; range, 3 mo to 83 y). Average rate of heparin infusion was 472.8 U/h (+/- 227). Success rates for graft thrombolysis were 90% (18 of 21). Success rates for native vessels were 79% (11 of 14). In patients who underwent only a low-dose protocol, the transfusion rate was 15% and major complications were 10%. In patients with a combined low-dose/high-dose administration, the transfusion rate was 46% and major complications were 13%. Overall success rate and major complication rates were 86% (30 of 35) and 11% (four of 35), respectively. Frequency of transfusions was 37% (13 of 35; mean, 2.8 U).

CONCLUSION

Although weight-adjusted dosing for rt-PA provides a high efficacy of relieving ischemia, the rate of complications, especially bleeding, seems excessive in comparison to historical experience with urokinase. Administration of short-term high doses of rt-PA did not appear to have any beneficial effect. Further investigation with lower dosing and concentration should be considered.

摘要

相似文献

1
Weight-based rt-PA thrombolysis protocol for acute native arterial and bypass graft occlusions.
J Vasc Interv Radiol. 2002 Jan;13(1):45-50. doi: 10.1016/s1051-0443(07)60008-6.
2
Transcatheter intraarterial infusion of rt-PA for acute lower limb ischemia: results and complications.经导管动脉内输注重组组织型纤溶酶原激活剂治疗急性下肢缺血:结果与并发症
J Vasc Interv Radiol. 2001 Apr;12(4):423-30. doi: 10.1016/s1051-0443(07)61879-x.
3
The association of periprocedural hypertension and adverse outcomes in patients undergoing catheter-directed thrombolysis.导管直接溶栓治疗患者围手术期高血压与不良结局的关联。
Ann Vasc Surg. 2010 Jul;24(5):609-14. doi: 10.1016/j.avsg.2009.12.011. Epub 2010 Apr 22.
4
Catheter-directed thrombolysis for acute limb ischemia caused by native artery occlusion: an experience of a university hospital.导管定向溶栓治疗原发性动脉闭塞所致急性肢体缺血:一所大学医院的经验
J Med Assoc Thai. 2013 Jun;96(6):661-8.
5
Bleeding complications associated with the use of rt-PA versus r-PA for peripheral arterial and venous thromboembolic occlusions.
Tech Vasc Interv Radiol. 2001 Jun;4(2):92-8. doi: 10.1016/s1089-2516(01)90002-2.
6
Initial experience with the combination of reteplase and abciximab for thrombolytic therapy in peripheral arterial occlusive disease: a pilot study.瑞替普酶与阿昔单抗联合用于外周动脉闭塞性疾病溶栓治疗的初步经验:一项试点研究。
J Vasc Interv Radiol. 2002 Jan;13(1):37-43. doi: 10.1016/s1051-0443(07)60006-2.
7
Complications associated with the use of urokinase and recombinant tissue plasminogen activator for catheter-directed peripheral arterial and venous thrombolysis.使用尿激酶和重组组织型纤溶酶原激活剂进行导管定向外周动脉和静脉溶栓相关的并发症。
J Vasc Interv Radiol. 2000 Mar;11(3):295-8. doi: 10.1016/s1051-0443(07)61420-1.
8
Using a peptide inhibitor of the glycoprotein IIb/IIIa platelet receptor: initial experience in patients with acute peripheral arterial occlusions.使用糖蛋白IIb/IIIa血小板受体的肽抑制剂:急性外周动脉闭塞患者的初步经验。
AJR Am J Roentgenol. 2002 Mar;178(3):617-22. doi: 10.2214/ajr.178.3.1780617.
9
Retrospective analysis of Rt-pa thrombolysis combined with PGE1 in patients with peripheral arterial occlusions.瑞替普酶溶栓联合前列地尔治疗周围动脉闭塞症患者的回顾性分析
Angiology. 2000 May;51(5):377-84. doi: 10.1177/000331970005100504.
10
The safety, efficacy, and pharmacoeconomics of low-dose alteplase compared with urokinase for catheter-directed thrombolysis of arterial and venous occlusions.低剂量阿替普酶与尿激酶用于导管定向溶栓治疗动静脉闭塞的安全性、有效性及药物经济学比较。
J Vasc Surg. 2003 Mar;37(3):512-7. doi: 10.1067/mva.2003.41.

引用本文的文献

1
Endovascular treatment for acute ischemic stroke patients: implications and interpretation of IMS III, MR RESCUE, and SYNTHESIS EXPANSION trials: A report from the Working Group of International Congress of Interventional Neurology.急性缺血性卒中患者的血管内治疗:IMS III、MR RESCUE及SYNTHESIS EXPANSION试验的意义与解读:国际介入神经病学大会工作组报告
J Vasc Interv Neurol. 2014 May;7(1):56-75.
2
Venous Thrombolysis: Current Perspectives.静脉溶栓:当前观点
Curr Treat Options Cardiovasc Med. 2004 Apr;6(2):159-168. doi: 10.1007/s11936-004-0044-1.